First AD

Second AD

ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL

Video content above is prompted by the following:

Another frontline triplet regimen being studied is how pirtobrutinib plus venetoclax and obinutuzumab. What are your thoughts on this combination, and do you foresee a place in therapy for it in the frontline setting?

Video Series

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASH 2024: Updates in the Treatment of CLL  

Peer Exchange

Panelists discuss how pirtobrutinib plus venetoclax and obinutuzumab shows promise as a frontline chronic lymphocytic leukemia (CLL) treatment option, with its high selectivity and favorable safety profile potentially offering advantages over current Bruton tyrosine kinase inhibitor–based regimens, though more long-term data is needed to determine its optimal place in therapy.

Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi

ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL

Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL

Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials

Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL